» Articles » PMID: 31092266

MIIP Inhibits the Growth of Prostate Cancer Via Interaction with PP1α and Negative Modulation of AKT Signaling

Overview
Publisher Biomed Central
Date 2019 May 17
PMID 31092266
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Over-activation of phosphatidylinositol 3-kinase (PI3K)-AKT-mammalian target of rapamycin (mTOR) signaling pathway is one of important mechanisms to promote castration resistant prostate cancer, the final stage of prostate cancer (PCa). Dysregulation of PP1-meditaed AKT dephosphorylation might contribute to such an event but is not fully understood. As a newly identified tumor suppressor, MIIP exerts its role in various types of cancer but has not been investigated in PCa.

Results: We first demonstrated that overexpression of migration and invasion inhibitory protein (MIIP) in human PCa cell lines suppresses their growth while knockdown of MIIP does the opposite in vitro. Although MIIP has no effect on the expression of AR and its target genes or the nuclear translocation of AR in AR-positive PCa cells, MIIP overexpression significantly inhibits activation of AKT-mTOR pathway in both AR- positive and negative PCa cells whereas knockdown of MIIP enhances AKT-mTOR signaling. Using Western blot, immunofluorescence co-localization and co-immunoprecipitation analysis, we found that MIIP interacts with PP1α via its C-terminal part but does not affect its protein level. Importantly, silence of PP1α reversed the inhibitory effect of MIIP on AKT phosphorylation and cell growth in PCa cell lines, while MIIP∆C, which is incapable of interacting with PP1α, loses MIIP's effect, suggesting that MIIP exerts its roles via interaction with PP1α. Further, MIIP overexpression inhibits the growth of both AR- positive and negative PCa xenograft in nude mice. Finally, immunohistochemical staining of PCa tissue microarray showed that MIIP expression level is downregulated in PCa and negatively correlated with Gleason score of PCa.

Conclusion: We discovered that MIIP is a novel suppressor of oncogenic AKT-mTOR signaling in PCa by facilitating PP1-meditaed AKT dephosphorylation. Our study further emphasized the tumor suppressive role of MIIP and illustrated a novel mechanism.

Citing Articles

GOLM1 promotes prostate cancer progression via interaction with PSMD1 and enhancing AR-driven transcriptional activation.

Yan G, Zhu T, Zhou J, Li X, Wen Z, Miuhuitijiang B J Cell Mol Med. 2024; 28(20):e70186.

PMID: 39470578 PMC: 11520440. DOI: 10.1111/jcmm.70186.


Cardiac-Specific Suppression of Valosin-Containing Protein Induces Progressive Heart Failure and Premature Mortality Correlating with Temporal Dysregulations in mTOR Complex 2 and Protein Phosphatase 1.

Sun X, Tang X, Qiu H Int J Mol Sci. 2024; 25(12).

PMID: 38928151 PMC: 11203954. DOI: 10.3390/ijms25126445.


GL-V9 inhibits the activation of AR-AKT-HK2 signaling networks and induces prostate cancer cell apoptosis through mitochondria-mediated mechanism.

Wang R, Min Q, Guo Y, Zhou Y, Zhang X, Wang D iScience. 2024; 27(3):109246.

PMID: 38439974 PMC: 10909900. DOI: 10.1016/j.isci.2024.109246.


VNP20009-Abvec-Igκ-MIIP suppresses ovarian cancer progression by modulating Ras/MEK/ERK signaling pathway.

Wang Q, Tang Y, Dai A, Li T, Pei Y, Zhang Z Appl Microbiol Biotechnol. 2024; 108(1):218.

PMID: 38372808 PMC: 10876780. DOI: 10.1007/s00253-024-13047-z.


MIIP downregulation drives colorectal cancer progression through inducing peri-cancerous adipose tissue browning.

Wang Q, Su Y, Sun R, Xiong X, Guo K, Wei M Cell Biosci. 2024; 14(1):12.

PMID: 38245780 PMC: 10800076. DOI: 10.1186/s13578-023-01179-0.


References
1.
Ryan C, Molina A, Griffin T . Abiraterone in metastatic prostate cancer. N Engl J Med. 2013; 368(15):1458-9. DOI: 10.1056/NEJMc1301594. View

2.
Lin Q, Buckler 4th E, Muse S, Walker J . Molecular evolution of type 1 serine/threonine protein phosphatases. Mol Phylogenet Evol. 1999; 12(1):57-66. DOI: 10.1006/mpev.1998.0560. View

3.
Perlmutter M, Lepor H . Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev Urol. 2007; 9 Suppl 1:S3-8. PMC: 1831539. View

4.
Shen M, Abate-Shen C . Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 2010; 24(18):1967-2000. PMC: 2939361. DOI: 10.1101/gad.1965810. View

5.
Wang Y, Hu L, Ji P, Teng F, Tian W, Liu Y . MIIP remodels Rac1-mediated cytoskeleton structure in suppression of endometrial cancer metastasis. J Hematol Oncol. 2016; 9(1):112. PMC: 5069779. DOI: 10.1186/s13045-016-0342-6. View